WHO's approval for Covaxin increased: World Health Organization said - trust in India's vaccine industry; Important meeting will be held on November 2

Posted on 29th Oct 2021 by rohit kumar

Whether or not Covaxin will get approval from WHO can be decided in the final meeting of the Technical Advisory Group to be held on November 2. Mariangela Simao, ADG of Medicine and Health Products at WHO, said during the press conference in Geneva that we have confidence in India's vaccine industry.

 

Bharat Biotech is providing us with data rapidly and continuously. The company has given the last installment of its data on October 18. Hyderabad-based company Bharat Biotech had applied to the WHO on April 19 for approval of the vaccine.

 

What is the Technical Advisory Committee of WHO?

When a vaccine company made in different countries goes to the WHO for emergency approval, the health organization constitutes a technical advisory committee. The task of this committee is to examine the data of trials of all phases of the vaccine and recommend approval to WHO if the data is found correct. WHO has also formed a technical committee for the vaccine.

 

Asked to submit final data

WHO hopes that the committee can approve by next week. WHO's ADG Mariangela Simao said that our technical advisory group has asked the company to submit data for the final risk-benefit assessment.

 

Questions raised over approval of China's 2 vaccines

Covaxin is getting delayed in getting emergency approval, while China's Sinovac and Sinoform got approval in less than 40 days. According to reports, both the companies were not asked to submit more data. Clarifying this, Simao gave the example of Coveshield of Serum Institute of India and said that earlier another Indian company had sought approval and it got approval in just 30 days. He said that WHO is in touch with Bharat Biotech. We will complete his investigation soon.

 

meeting on 2nd November

Simao said that in the technical committee meeting held on October 26, Bharat Biotech was asked to give further clarifications. On November 2, there will be a meeting regarding the Advisory Group Final Risk-Benefit Assessment.

Other news